Probiotyki a prewencja i leczenie chorob przewodu pokarmowego czlowieka

• Autorzy: Wozniak-Kosek A , Jarosz M.

Warianty tytułu

EN

Probiotics and prevention, treatment of human gastrointestinal diseases

• Języki publikacji: PL

Słowa kluczowe

PL

mikroflora jelitowa; choroby czlowieka; choroby przewodu pokarmowego; prewencja; probiotyki; leczenie; zywienie czlowieka

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2005
• Tom: 32
• Numer: 4
• Opis fizyczny: s.366-375,rys.,tab.,bibliogr.

Twórcy

autor

Wozniak-Kosek A

• Instytut Zywnosci i Zywienia, Warszawa

autor

Jarosz M.

Bibliografia

• 1. Aiba Y., Suzuki N., Kabir A.M., et al.: Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probio- tic in a gnotobiotic murine model. Am. J. Gastroenterol., 1998, 93, 2097-2101.
• 2. Alm L.: Effect of fermentation on lactose, glucose and galactose content in milk and suitability of fermented milk products for lactose individuals. J. Dairy Sei., 1982, 65, 346-352.
• 3. Armuzzi A., Cremonini E, Bartolozzi F., et al.: The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side- effects during Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther., 2001, 15, 163-169.
• 4. Aso Y., Akazan H. BLP Study Group: Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cncer. Urol. Int., 1992, 49, 125-129.
• 5. Aso Y.: Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur. Urol., 1995, 27, 104-109.
• 6. Biselli R., Tzantzoglou S., Fattorossi A.: Lactic acid bacteria modulate adhesive molecule expression and hydrogen peroxidate production by human polymorphonuclear leukocytes. J. Immunol. Immunopharmacol., 1996, 16, 7-10.
• 7. Black F.T.: A study of the recovery of ingested encapsulated Lactobacillus acidopholus and Bifidobacterium bifidum from duodenal fluid and feaces. Clin. Dept. Chr. Hansen's. Bio System A/S Horsholm 1988.
• 8. Canducci F. Armuzzi A., Cremonini F., et al.: A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment. Pharmacol. Ther., 2000, 14, 1625-1629.
• 9. Coconnier M.H., Lievin V, Lorot M., Servin A.L.: Antagonistic activity of Lactobacillus acidophilus LB against intracellular Salmonella entérica serovar Typhimurium infecting human enterocyte-like Caco-2/TC-7 cells. Appl. Environ. Microbiol., 2000, 66, 1152-1157.
• 10. Cremonini F., Di Caro S., Covino M.: Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study, Am. J. Gastroenterol., 2002, 97, 2744-2749.
• 11. Cremonini F.: Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther., 2002, 16, 1461-1467.
• 12. Danysz A.: Probioza w profilaktyce i leczeniu niektórych chorób przewodu pokarmowego. Nowa Med. 1997, 4, 17-23.
• 13. D'Souza A.L.: Probiotics in prewention of antibiotic-associated diarrhoea:meta-analysis. Br. Med. J., 2002, 324, 1361-1368.
• 14. Felley C.P., Corthesy-Theulaz I., Rivero J.L., et al.: Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man, Eur. J. Gastroenterol. Hepatol., 2001, 13, 25-29.
• 15. Gilliland S.E., Nelson C.R., Maxwell C.: Assimilation of cholesterol by Lactobacillus acidophilus. Appl. Environ. Microbiol., 1985, 49, 377- 381
• 16. Gionchetti P, Rizzello F., Venturi A.: Oral bacteriotheraphy as maintenance treatment in patients with chromic pouchitis. A double-blind, placebo-controlled trial. Gastroenterology, 2000, 119, 305-309.,
• 17. Goldin B.R., Gorbach S.L.: Effect of Lactobacillus acidophilus dietary supplements on 1,2-dimethylhydrazine dihydrochloride induced intestinal cancer in rats. J. Natl. Canncer Inst., 1980, 64, 263-265.
• 18. Goldin B.R., Gorbach S.L.: The effect of milk and lactobacillus feeding on human intestinal bacterial enzymes activity. Am. J. Clin. Nutr., 1984, 39, 756- 761.- 18a. Gorbach S.L.: Lactic acid bacteria and human health. Ann. Med., 1990, 22, 37-41.
• 19. Gwee K.A.: Postinfectious Irritable Bowel Syndrome. Curr. Treat. Options Gastroenterol., 2001, 4, 4, 287-291.
• 20. Hooker K.D., DiPiro J.T.: Effect of antimicrobial therapy on bowel flora. Clin. Pharm., 1988, 7, 22, 878-888.
• 21. Isolauri E., Majamaa H., Arvola T.: Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1992, 105, 1643-1650.
• 22. Katz J.A., Fiocchi C.: Probiotic therapy of IBD. IBD Monitor, 2001, 2, 106-111.
• 23. Kim H.S. Gilliland S.E.: Lactobacillus acidophilus as a dietary adjunct for milk to acid lactose digestion in humans. J. Dairy
• Sei., 1983, 66, 959-966.
• 24. Kolars J.C., Levitt M.D., Aouji M., Savaiano D.A.: Yogurt-an autodigesting source of lactose. N.Engl. J. Med., 1984, 3210, 1-3.
• 25. Kruis W., Schultz E., Fixa P.: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther., 1997, 11, 853-858.
• 26. Libudzisz Z.: Mikrobiologiczne i techniczne aspekty probiotyków. Materiały z warsztatów „Probiotyki". Kraków, czerwiec 2002.
• 27. Madsen K., Cornish A., Soper R: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121, 580-591.
• 28. Mattar A.F, Drongowski R.A., Coran A.G.: Effect on probiotic on enterocyte bacterial translocation in vivo. Pediatr. Surg. Int., 2001, 17, 265-268.
• 29. Mendall M. A., Kumar D.: Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur. J. Gastroenterol. Hepatol., 1998, 10, 1, 59-62.
• 30. Michetti P. Dorta D., Wiesel H.P., et al.: Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) Lai on Helicobacter pylori infection in humans, Digestion 1999, 60, 203-209.
• 31. Pinchuk I.V Bressollier P, Verneuil B., et al.: In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics, Antimicrob. Agents Chemother., 2001, 45, 3156-3161.
• 32. O'Sullivan M.A., O'Morain C.A.: Bacterial supplementation in the irritable bowel syndrome. A randomized double-bind placebo-controlled crossover study. Dig. Dis. Sei., 2000, 32, 302-304.
• 33. Reddy B.S., Rivenson A.: Inhibitory effect at Bifidobacterium longum on colon, mammary and liver carcinogenesis induced by 2-amina-3-methy-limidazal [4,5-t] quinoline, a food mutagen. Cancer Res., 1993, 53, 3914-3918.
• 34. Ryżko J.: Zastosowanie probiotyków i prebiotyków w leczeniu nieswoistych zapaleń jelit oraz zaburzeń czynnościowych jelita grubego. Pediatr. Współ., 2002, 1, 55-60.
• 35. Sakamoto I., Igarashi M., Kimura K, et al.: Suppressive effect of Lactobacillus gasseri OLL2716 (LG21) on Helicobacter pylori infection in humans. J. Antimicrob. Chemother. 2001, 47, 709-710.
• 36. Shanahan F.: Inflammatory bowel disease: immuno- diagnostics, immunotherapeutics and ecotheraopeutics. Gastroenterology 2001, 120, 622-636.
• 37. Salminen S., Ouwehand A.C., Isolauri E.: Clinical applications of probiotic bacteria. Int. Dairy J. 1998, 8, 563-572.
• 38. Sheu B.S., Wu J.J., Lo C.Y., et al.: Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther., 2002 Sep., 16, 1669-75.
• 39. Socha J. (red.) Gastroenterologia praktyczna. Warszawa, WL PZWL, 1999.
• 40. Woźniak-Kosek A., Jarosz M.: Probiotyki a żywienie człowieka. Żyw. Człow. Metab., 2005, 1, 72-83.
• 41. Zabala A.: Anti-proliferative effect of two lactic acid bacteria strains of human origin on the growth of a myeloma cell line. Lett. Appl. Microbiol., 2001, 32, 287-292.